{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+for+Covid-19&page=4",
    "query": {
      "intervention": "Standard of Care for Covid-19",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 209,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+for+Covid-19&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+for+Covid-19&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T19:33:32.693Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04707664",
      "title": "Sargramostim Use in COVID-19 to Recover Patient Health",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Sargramostim",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Partner Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2021-04-27",
      "completion_date": "2022-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-02-06",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04707664"
    },
    {
      "nct_id": "NCT04425720",
      "title": "Use of Remote Monitoring for COVID-19 Patient",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID"
      ],
      "interventions": [
        {
          "name": "LifeSignals Biosensor 1AX*",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 300,
      "start_date": "2020-09-01",
      "completion_date": "2021-12-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04425720"
    },
    {
      "nct_id": "NCT04433949",
      "title": "Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia",
        "Severe Acute Respiratory Syndrome",
        "Symptomatic COVID-19 Infection Laboratory-Confirmed"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Low Dose Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-06-23",
      "completion_date": "2024-05-30",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433949"
    },
    {
      "nct_id": "NCT04629703",
      "title": "Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19",
        "SARS (Severe Acute Respiratory Syndrome)",
        "SARS Pneumonia",
        "SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere",
        "Pneumonia",
        "Pneumonia, Viral"
      ],
      "interventions": [
        {
          "name": "Fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 280,
      "start_date": "2021-03-25",
      "completion_date": "2022-09-05",
      "has_results": false,
      "last_update_posted_date": "2023-08-18",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 9,
      "location_summary": "Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04629703"
    },
    {
      "nct_id": "NCT04397757",
      "title": "COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "COVID-19 Convalescent Plasma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2020-05-13",
      "completion_date": "2021-03-08",
      "has_results": true,
      "last_update_posted_date": "2022-04-19",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04397757"
    },
    {
      "nct_id": "NCT03656926",
      "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bronchiolitis Obliterans",
        "Chronic Rejection of Lung Transplant",
        "Lung Transplant Rejection",
        "Lung Transplant; Complications",
        "Lung Transplant Failure and Rejection",
        "Chronic Lung Allograft Dysfunction"
      ],
      "interventions": [
        {
          "name": "Liposomal Cyclosporine A",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zambon SpA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2019-03-26",
      "completion_date": "2024-03-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03656926"
    },
    {
      "nct_id": "NCT04352985",
      "title": "Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Septic Shock",
        "Endotoxemia",
        "COVID",
        "Corona Virus Infection",
        "Sepsis, Severe"
      ],
      "interventions": [
        {
          "name": "Toraymyxin PMX-20R (PMX Cartridge)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Spectral Diagnostics (US) Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 3,
      "location_summary": "Farmington, Connecticut • Washington D.C., District of Columbia • Stony Brook, New York",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04352985"
    },
    {
      "nct_id": "NCT04646044",
      "title": "A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid-19",
        "Coronavirus Disease 2019"
      ],
      "interventions": [
        {
          "name": "Bempegaldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-11-13",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 4,
      "location_summary": "Hialeah, Florida • Winter Park, Florida • Mesquite, Texas",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Mesquite",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04646044"
    },
    {
      "nct_id": "NCT04706416",
      "title": "N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronavirus",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "N-acetyl glucosamine (NAG)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Quantinosis.ai LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 150,
      "start_date": "2020-11-14",
      "completion_date": "2021-01-15",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 1,
      "location_summary": "Harlingen, Texas",
      "locations": [
        {
          "city": "Harlingen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04706416"
    },
    {
      "nct_id": "NCT04593940",
      "title": "Immune Modulators for Treating COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "cenicriviroc (closed to enrollment as of 3-Sep-2021)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Benjamin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1971,
      "start_date": "2020-10-15",
      "completion_date": "2022-03-05",
      "has_results": true,
      "last_update_posted_date": "2023-09-25",
      "last_synced_at": "2026-10-08T19:33:32.693Z",
      "location_count": 67,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 54 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Moreno Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04593940"
    }
  ]
}